It’s been awhile since we checked in with our Chardonnay guzzling friends in Paris as well we weren’t sure they were still in diabetes. Now they have not sold off or closed their diabetes franchise as Johnson and Johnson (NYSE: JNJ) has done, although given the way things are going in Paris they might want to consider this option. Listen this is the wacky world of diabetes where anything can and usually does happen even when it makes no sense whatsoever.
Unfortunately, it appears that Sanofi (NYSE: SNY) is a glutton for punishment and wants to remain in . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.